Literature DB >> 2821832

Role of adenosine in noradrenergic neurotransmission in spontaneously hypertensive rats.

E K Jackson1.   

Abstract

The purpose of this study was to compare the in vivo role of adenosine as a modulator of noradrenergic neurotransmission in the spontaneously hypertensive rat (SHR) and Wistar-Kyoto control rat (WKY). In the in situ blood-perfused rat mesentery, vascular responses to periarterial (sympathetic) nerve stimulation (PNS) and to exogenous norepinephrine (NE) were enhanced in SHR compared with WKY. In both SHR and WKY, vascular responses to PNS were more sensitive to inhibition by adenosine than were responses to NE. At matched base-line vascular responses, compared with WKY, SHR were less sensitive to the inhibitory effects of adenosine on vascular responses to PNS, but SHR and WKY were equally sensitive with respect to adenosine-induced inhibition of responses to NE. Antagonism of adenosine receptors with 1,3-dipropyl-8-p-sulfophenylxanthine shifted the dose-response curve to exogenous adenosine sixfold to the right yet did not influence vascular responses to PNS or NE in either SHR or WKY. Furthermore, PNS did not alter either arterial or mesenteric venous plasma levels of adenosine in SHR or WKY, and plasma levels of adenosine in both strains were always lower than the calculated threshold level required to attenuate neurotransmission. It is concluded that in vivo 1) exogenous adenosine interferes with noradrenergic neurotransmission in both SHR and WKY; 2) SHR are less sensitive to the inhibitory effects of exogenous adenosine on noradrenergic neurotransmission than are WKY; 3) endogenous adenosine does not play a role in modulating neurotransmission in either strain under the conditions of this study; and 4) enhanced noradrenergic neurotransmission in the SHR is not due to defective modulation of neurotransmission by adenosine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821832     DOI: 10.1152/ajpheart.1987.253.4.H909

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Adenosine inhibits renin release induced by suprarenal-aortic constriction and prostacyclin.

Authors:  G Deray; R A Branch; A Ohnishi; E K Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

2.  Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.

Authors:  Edwin K Jackson; Dongmei Cheng; Stevan P Tofovic; Zaichuan Mi
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-23

3.  Role of endogenous adenosine in vasovagal syncope.

Authors:  M Sinkovec; A Grad; P Rakovec
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

4.  Modulation by nicotinamide adenine dinucleotide of sympathetic and sensory-motor neurotransmission via P1-purinoceptors in the rat mesenteric arterial bed.

Authors:  V Ralevic
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  Augmented sensory-motor vasodilatation of the rat mesenteric arterial bed after chronic infusion of the P1-purinoceptor antagonist, DPSPX.

Authors:  V Relevic; A Rubino; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Enhanced sympathetic neurotransmission in the tail artery of 1,3-dipropyl-8-sulphophenylxanthine (DPSPX)-treated rats.

Authors:  P Karoon; A Rubino; G Burnstock
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors.

Authors:  U Windscheif; V Ralevic; H G Bäumert; E Mutschler; G Lambrecht; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

8.  Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed.

Authors:  A Rubino; V Ralevic; G Burnstock
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.